With regards to hepatic fibrosis, there was a slight reduction in the LSM and FIB-4 index with use of SGLT-2 inhibitors in comparison to controls among non-alcoholic fatty liver patients with Type 2 diabetes mellitus. This evidence concerns the gene SLC5A2 and fatty liver disease.